A 58-year-old man with dilated cardiomyopathy and NYHA Class III heart failure is being counselled on disease-modifying pharmacotherapy. Which of the following is NOT a cornerstone agent in the management of systolic heart failure?

Question

Accepted Answer

D. Calcium channel blocker (diltiazem or verapamil). ## Cornerstone Agents in Systolic Heart Failure

**Key Point:** The foundational pharmacotherapy for systolic HF (reduced ejection fraction) rests on four pillars: ACE-I/ARB, beta-blockers, aldosterone antagonists, and SGLT2 inhibitors. Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are NOT part of this core regimen and may even be harmful in systolic HF.

### Why Each Agent Works

| Agent Class | Mechanism | Indication in HFrEF |
|---|---|---|
| ACE-I / ARB | Blocks angiotensin II → reduces afterload, remodelling | **Cornerstone** — reduce mortality |
| Beta-blocker | Reduces sympathetic drive, improves contractility over time | **Cornerstone** — reduce mortality (only bisoprolol, carvedilol, metoprolol succinate proven) |
| Aldosterone antagonist | Blocks aldosterone → reduces fibrosis, K^+^ retention | **Cornerstone** — reduce mortality in moderate–severe HF |
| Non-DHP CCB (diltiazem, verapamil) | Negative inotrope, slows AV conduction | **Contraindicated** in systolic HF — worsens outcomes |
| DHP CCB (amlodipine, nifedipine) | Vasodilator, no negative inotropy | Neutral in HFrEF; used only for hypertension/angina |

**High-Yield:** Diltiazem and verapamil depress myocardial contractility and are explicitly avoided in systolic HF. They may be used in HFpEF for rate control or hypertension, but never as primary therapy in reduced EF.

### Mnemonic for HFrEF Pillars
**ABCD-S:**
- **A** — ACE-I / ARB
- **B** — Beta-blocker (evidence-based: bisoprolol, carvedilol, metoprolol succinate)
- **C** — (Aldosterone antagonist — "C" for "Cardiac remodelling block")
- **D** — Diuretics (symptom relief, not mortality benefit)
- **S** — SGLT2 inhibitor (newer cornerstone: dapagliflozin, empagliflozin)

**Clinical Pearl:** Non-dihydropyridine CCBs (verapamil, diltiazem) are negative inotropes and should be avoided in HFrEF. If rate control is needed, use a beta-blocker or ivabradine instead.

**Warning:** Do not confuse dihydropyridine CCBs (amlodipine, nifedipine — vasodilators, neutral in HFrEF) with non-dihydropyridines (diltiazem, verapamil — contraindicated). Amlodipine is safe in HFrEF but offers no mortality benefit.

Answer

A. Aldosterone antagonist (spironolactone or eplerenone)

Answer

B. ACE inhibitor or ARB

Answer

C. Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)

A 58-year-old man with dilated cardiomyopathy and NYHA Class III heart failure is being counselled on disease-modifying pharmacotherapy. Which of the following is NOT a cornerstone agent in the management of systolic heart failure?

Explanation

Cornerstone Agents in Systolic Heart Failure

Why Each Agent Works

Mnemonic for HFrEF Pillars

Practice similar questions

Join our NEET PG community

Agent Class	Mechanism	Indication in HFrEF
ACE-I / ARB	Blocks angiotensin II → reduces afterload, remodelling	Cornerstone — reduce mortality
Beta-blocker	Reduces sympathetic drive, improves contractility over time	Cornerstone — reduce mortality (only bisoprolol, carvedilol, metoprolol succinate proven)
Aldosterone antagonist	Blocks aldosterone → reduces fibrosis, K⁺ retention	Cornerstone — reduce mortality in moderate–severe HF
Non-DHP CCB (diltiazem, verapamil)	Negative inotrope, slows AV conduction	Contraindicated in systolic HF — worsens outcomes
DHP CCB (amlodipine, nifedipine)	Vasodilator, no negative inotropy	Neutral in HFrEF; used only for hypertension/angina